<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03356834</url>
  </required_header>
  <id_info>
    <org_study_id>HumanityHGLC</org_study_id>
    <nct_id>NCT03356834</nct_id>
  </id_info>
  <brief_title>Change of Renal Function and Bone Mineral Density in CHB Patients Switch From TDF to TAF vs. Maintaining TDF</brief_title>
  <acronym>SWITAF</acronym>
  <official_title>Change of Renal Function and Bone Mineral Density Marker in Chronic Hepatitis B Patients Switching From TDF to TAF vs. Maintaining TDF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Humanity and Health Research Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Humanity and Health Research Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In Chronic hepatitis B (CHB) patients receiving long-term sequential Neucleos(t)ides(NAs),
      majority of these CHB patients experienced drug resistance and switched to Tenofovir
      disoproxil fumaratate(TDF). However, some of patients on long term TDF experienced impairment
      of renal function and bone mineral density. After Tenofovir alafenamide(TAF) was in clinical
      practice, these group of patients got an clinical option to switch from TDF to TAF. The
      investigators designed a prospective cohort study to evaluate the real life effectiveness and
      safety in participants with chronic HBV infection switch from TDF to TAF vs. maintaining on
      TDF.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tenofovir disoproxil fumarate(TDF) have been associated with renal toxicity and reduced bone
      mineral density. Tenofovir alafenamide(TAF) is a novel tenofovir prodrug that reduces
      tenofovir plasma concentrations by 90%, thereby decreasing off-target side-effects. The
      investigators aimed to assess whether efficacy, safety, and tolerability were non-inferior in
      participants switched to TAF versus in those remaining on TDF. This is a prospective clinical
      study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antiviral response of TAF</measure>
    <time_frame>60 months</time_frame>
    <description>Anti-HBV effectiveness of TAF compared with TDF in treatment experienced CHB patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of renal function and bone mineral density in CHB patients switching to TAF</measure>
    <time_frame>60 months</time_frame>
    <description>Change of renal function and bone mineral density from baseline in CHB patients of TAF a group compared with TDF group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>TDF switch to TAF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tenofovir Disoproxil Fumarate(TDF) 300mg daily switch to Tenofovir Alafenamide(TAF) 25mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintaining on TDF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Maintaining on Tenofovir Disoproxil Fumarate(TDF) 300mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir alafenamide(TAF)</intervention_name>
    <description>25 mg tablet administered orally once daily</description>
    <arm_group_label>TDF switch to TAF</arm_group_label>
    <other_name>VEMLIDY®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir disoproxil fumarate(TDF)</intervention_name>
    <description>300 mg tablet administered orally once daily</description>
    <arm_group_label>Maintaining on TDF</arm_group_label>
    <other_name>VIREAD®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Chronic hepatitis B,

          2. Antiviral experienced,

          3. Currently on long term TDF anti-HBV treatment,

          4. HBV DNA &lt; 6 log IU/ml (LLOD)

          5. Able to sign the consent form of anticipating in the study

        Exclusion Criteria:

          1. Co-infected with HCV, HIV or other viral hepatitis,

          2. Diagnosis of HCC
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cheng Wang, M.D. PhD</last_name>
    <phone>21539831</phone>
    <email>wangcheng@hnhmgl.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yudong Wang, PhD</last_name>
    <phone>21539831</phone>
    <email>dannywang@hnhmgl.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Humanity and Health GI and Liver Centre</name>
      <address>
        <city>Hong Kong</city>
        <zip>00852</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George KK Lau, MD</last_name>
      <phone>(852)28613777</phone>
      <email>gkklau@netvigator.com</email>
    </contact>
    <contact_backup>
      <last_name>Cheng Wang, M.D, PhD</last_name>
      <phone>21539831</phone>
      <email>wangcheng@hnhmgl.com</email>
    </contact_backup>
    <investigator>
      <last_name>George KK Lau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2017</study_first_submitted>
  <study_first_submitted_qc>November 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2017</study_first_posted>
  <last_update_submitted>February 1, 2018</last_update_submitted>
  <last_update_submitted_qc>February 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Humanity and Health Research Centre</investigator_affiliation>
    <investigator_full_name>George Lau</investigator_full_name>
    <investigator_title>Humanity &amp; Healthy Medical Group President</investigator_title>
  </responsible_party>
  <keyword>Chronic hepatitis B</keyword>
  <keyword>Efficacy, safety, and tolerability</keyword>
  <keyword>Tenofovir alafenamide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

